Evidence map›Paper›PMID 40453292›Full record

ArticleCureus2025

Optimizing Positron Emission Tomography-Computed Tomography (PET-CT) Use in Colorectal Cancer: Identifying Patients at High Risk of Recurrence.

Takaaki Fujimoto, Koji Tamura, Kinuko Nagayoshi, Yusuke Mizuuchi, Ayaka Ikeda, Yuichi Tanaka, Naoki Ikenaga, Kohei Nakata, Kenoki Ohuchida, Masafumi Nakamura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takaaki FujimotoDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Koji TamuraDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Kinuko NagayoshiDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Yusuke MizuuchiDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Ayaka IkedaDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Yuichi TanakaDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Naoki IkenagaDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Kohei NakataDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Kenoki OhuchidaDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.
Masafumi NakamuraDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction This study aimed to evaluate the prognostic significance of preoperative positron emission tomography-computed tomography (PET-CT) in resectable colorectal cancer (CRC), specifically examining the association between standardized uptake value max (SUVmax) and recurrence risk, stratified by pathological stage. Methods A retrospective analysis was conducted on 164 CRC patients who underwent PET-CT before curative resection. SUVmax values were assessed for their correlation with overall survival (OS) and recurrence-free survival (RFS). Receiver operating characteristic (ROC) curve analysis was used to determine the SUVmax cutoff for recurrence prediction. Multivariate Cox regression identified independent prognostic factors. Results In stage 3 CRC, SUVmax was significantly associated with recurrence risk, with a cutoff of 13.5 (area under the ROC curve (AUC) = 0.72,

Indexed as

colorectal cancerpet-ct scanrecurrence predictionstandardized uptake value (suv max)tumor marker

Identifiers

PMID40453292
PMCPMC12123389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.